We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genomic Data Affects Prognosis of Advanced Prostate Cancer

By LabMedica International staff writers
Posted on 22 May 2019
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome.

Various genomic and histologic features of prostate cancer have been described as conferring a worse prognosis. More...
Among these is the presence of neuroendocrine or small-cell characteristics in tumors, sometimes referred to as aggressive variant prostate cancer or neuroendocrine prostate cancer.

A large international team of scientists led by the Memorial Sloan Kettering Cancer Center (New York, NY, USA) used exome sequencing and RNA sequencing to assess coding mutations and transcriptomic features in samples from more than 400 individuals with metastatic, castration-resistant prostate cancer (mCRPC) who also had clinical data available. They focused on a matched tumor-normal dataset for 429 mCRPC patients treated at seven centers around the world, using exome sequencing to profile coding alterations in 444 prostate, lymph node, bone, liver, lung, or other biopsy samples from these cases. They also performed RNA sequencing on 332 tumor samples from a subset of 323 mCRPC patients.

Reviews were conducted on H&E-stained frozen sections, allowing for review of the exact material that was used for nucleic acid extraction. Flash-frozen needle biopsies and matched normal samples underwent nucleic acid extraction and extracted DNA underwent whole-exome library construction and somatic mutation analysis. Amplifications and homozygous deletions for a set of 20 genes previously implicated in prostate cancer underwent further confirmatory review of segmentation files. Transcriptome libraries were prepared using polyA+ RNA isolation, or captured using Agilent SureSelect Human All Exon V4 reagents or in some cases using both polyA and capture methods.

The team used these genomic and transcriptomic data, and looked at the frequency and interactions between new and known genomic alterations in the advanced prostate cases, identifying frequent mutations in genes such as the androgen receptor gene AR, ETS, TP53, or PTEN, as well as co-occurring alterations affecting genes such as CDK12, CDK4, and CCND1 that fall in cell cycle pathways previously linked to potential immune activity against tumors. When they focused on 18 recurrently mutated genes in 128 patients who received androgen receptor signaling inhibitor drugs, they saw ties between relapse, or shorter time on treatment, and shifts in genes such as AR, TP53, or RB1. The RB1 gene alterations alone showed significant interactions with patient survival following androgen receptor signaling inhibitor treatment, the scientists reported, though chromosomal aneuploidy in general also tended to correspond with shorter survival times and relapse.

The authors concluded that that RB1 loss is the molecular factor most strongly associated with poor clinical outcomes in a contemporary cohort, highlighting the need for further investigation into mechanisms of resistance to AR therapies induced by loss of RB, and potential therapeutic strategies targeting this mechanism. The study was published on May 6, 2019, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Memorial Sloan Kettering Cancer Center


New
Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.